$Hutchmed (China) (HCM.US)$
China Approves First-Ever EZH2 Inhibitor: HUTCHMED's Breakthrough Lymphoma Treatment

$Hutchmed (China) (HCM.US)$
HUTCHMED's Lung Cancer Drug Shows Breakthrough 56% Response Rate in Latest Trial Data

$Hutchmed (China) (HCM.US)$
Major Breakthrough: HUTCHMED's Advanced Kidney Cancer Treatment Achieves Clinical Trial Success

when you start to wonder what US bank JP.M got to do with you
$Hutchmed (China) (HCM.US)$

$HUTCHMED (00013.HK)$ 👀 potential tight pivot bo

$HUTCHMED (00013.HK)$ 52w hi ✌️

$HUTCHMED (00013.HK)$ bo 🎉

$HUTCHMED (00013.HK)$ 👀 tight pivot

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies (ITCI.US)$  Phase 3
$CG Oncology (CGON.US)$  Phase 3
$Hutchmed (China) (HCM.US)$  Phase 3
$Viracta Therapeutics (VIRX.US)$  Phase 3
$GlycoMimetics (GLYC.US)$  Phase 3
$Annexon (ANNX.US)$  Phase 3
$Lipocine (LPCN.US)$  Phase 3
$FibroGen (FGEN.US)$  Phase 3
$UroGen Pharma Ltd (URGN.US)$  Phase 3
$Lyra Therapeutics (LYRA.US)$  Phase 3
$Citius Pharmaceuticals (CTXR.US)$  Phase 3
$Marinus Pharmaceuticals (MRNS.US)$  Phase 3
$BioCardia (BCDA.US)$  Phase 3...

Shares of $LianBio (LIAN.US)$ — which focuses on “developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries” — are soaring on Tuesday. Earlier this morning, the company announced a key agreement with $Bristol-Myers Squibb (BMY.US)$ regarding exclusive rights to a cardiovascular therapeutic. Subsequently, LIAN stock is up more than 130% as of this writing.
According to the ac...